AVGR - Avinger, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.37
-0.06 (-4.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.43
Open1.41
Bid1.38 x 1200
Ask1.50 x 500
Day's Range1.37 - 1.45
52 Week Range0.95 - 25.20
Volume291,511
Avg. Volume1,874,653
Market Cap7.621M
Beta1.21
PE Ratio (TTM)N/A
EPS (TTM)-49.25
Earnings DateMay 2, 2018 - May 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.25
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Avinger Announces Pricing of $3.55 Million Registered Direct Offering

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 2,166,180 shares of common stock at a price of $1.6425 per share in a registered direct offering, resulting in total gross proceeds of approximately $3.55 million. The Company also agreed to issue unregistered warrants to the investors in a concurrent private placement to purchase up to 0.5 share of common stock for each share purchased with an exercise price of $1.58 per share. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., (NYSE American:LTS) is acting as exclusive placement agent for the registered direct offering and concurrent private placement.

  • GlobeNewswire12 days ago

    Avinger Appoints Jaafer Golzar, MD, FACC, FSCAI, as Chief Medical Officer

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the appointment, effective immediately, of Jaafer Golzar, MD, as the Company’s Chief Medical Officer. Dr. Golzar is a practicing interventional cardiologist with Advocate Medical Group in Chicago.

  • Avinger Stock Up 16% on Pantheris Device US Launch
    Market Realist25 days ago

    Avinger Stock Up 16% on Pantheris Device US Launch

    Yesterday, Avinger (AVGR) stock rose ~16% as the company announced the successful treatment of its first patients with its next-gen Pantheris device for PAD (peripheral artery disease). The successful treatment of these patients with the Pantheris device lays the foundation for the device’s expanded US launch. Avinger has achieved one of its key milestones, as the image above shows.

  • ACCESSWIRE25 days ago

    Today’s Research Reports on Stocks to Watch: Achaogen and Avinger

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Shares of Achaogen were plummeting in Tuesday trading after the FDA cleared the way for its Zemdri as a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae but issued a complete response letter for the drug as a potential treatment option for blood stream infection. Shares of Avinger were soaring after the company announced a positive initial case experience using the company's next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).

  • ACCESSWIRE25 days ago

    Initiating Free Research Reports on Avinger and Three Other Medical Equipment Equities

    Pre-market today, WallStEquities.com scans the following Medical Appliances and Equipment stocks: Amedica Corp. (NASDAQ: AMDA), Avinger Inc. (NASDAQ: AVGR), AxoGen Inc. (NASDAQ: AXGN), and Corindus Vascular Robotics Inc. (NYSE AMER: CVRS).

  • GlobeNewswire26 days ago

    Avinger Announces Successful Treatment of First Patients with Next-Generation Pantheris in Several Centers throughout the US

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that several physicians have successfully treated over 40 patients in the US across 13 sites with the next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD). The next-generation Pantheris design includes a simplified single balloon system for cutter apposition and blood flow management, a stiffer shaft for increased pushability, a more robust nosecone with the option for more tissue storage capacity, and an enhanced cutter design. Dr. Glen Schwartzberg, a vascular surgeon at Baton Rouge General, was the first physician in the United States to use both versions of the next-generation device, the Pantheris A400 standard nosecone and Pantheris A400X extended nosecone, in separate cases.

  • Avinger Inc (NASDAQ:AVGR): Is Breakeven Near?
    Simply Wall St.27 days ago

    Avinger Inc (NASDAQ:AVGR): Is Breakeven Near?

    Avinger Inc’s (NASDAQ:AVGR): Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) inRead More...

  • GlobeNewswirelast month

    Avinger’s Ocelot Technology Featured in Live Case Transmission at Complex Cardiovascular Catheter Therapeutics (C3) 2018

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Ocelot image-guided chronic total occlusion (CTO) crossing device was featured in a live case on June 19th at Complex Cardiovascular Catheter Therapeutics (C3) 2018 in Orlando, Florida. Ocelot combines real-time image guidance using optical coherence tomography (OCT) with a proprietary CTO crossing catheter design to aid physicians in the treatment of chronic total occlusions. Dr. Mahir Elder, an interventional cardiologist at the Detroit Medical Center Cardiovascular Institute, performed the case.

  • GlobeNewswirelast month

    Avinger Announces First Patients Enrolled in Post-Market Study Comparing Pantheris OCT Imaging to Intravascular Ultrasound

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the initiation of the SCAN study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. OCT is a light-based, high definition imaging modality, which generates no X-ray radiation. Avinger’s proprietary Lumivascular technology utilizes OCT to provide real-time intravascular imaging during the treatment of peripheral artery disease.

  • GlobeNewswirelast month

    Avinger Appoints Mark Weinswig as Chief Financial Officer

    Avinger, Inc. (AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Mark Weinswig will join the Company, and serve in the role of Chief Financial Officer (CFO) effective June 25, 2018. Mr. Weinswig will succeed Matt Ferguson, who will be leaving the Company to pursue other opportunities. Mr.  Ferguson will remain a full-time employee of Avinger until August 1, 2018, and continue as a consultant through December 31, 2018, to ensure a smooth transition.

  • Loss-Making Avinger Inc (NASDAQ:AVGR) Expected To Breakeven
    Simply Wall St.last month

    Loss-Making Avinger Inc (NASDAQ:AVGR) Expected To Breakeven

    Avinger Inc’s (NASDAQ:AVGR): Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) inRead More...

  • GlobeNewswire2 months ago

    Avinger Announces Presentations and Posters Featuring Lumivascular Technology at New Cardiovascular Horizons Annual Conference

    REDWOOD CITY, Calif., May 30, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, today announced a schedule of sessions and posters highlighting the company’ ...

  • GlobeNewswire2 months ago

    Avinger to Present at the 8th Annual LD Micro Invitational

    REDWOOD CITY, Calif., May 29, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, announced today that it will be presenting at the 8 th Annual LD Micro Invitational ...

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Avinger and Three More Medical Equipment Stocks

    Under evaluation this morning are these four stocks: Avinger Inc. (NASDAQ: AVGR), AxoGen Inc. (NASDAQ: AXGN), Corindus Vascular Robotics Inc. (NYSE AMER: CVRS), and Edwards Lifesciences Corp. (NYSE: EW). Redwood City, California headquartered Avinger Inc.'s stock finished last Friday's session 2.03% higher at $2.01.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Avinger and Cara Therapeutics

    NEW YORK, NY / ACCESSWIRE / May 24, 2018 / Avinger, Inc. and Cara Therapeutics were both exploding in Wednesday trading on positive news. Avinger shares blasted off after the company announced it had gained ...

  • Avinger Inc Stock Goes Gangbusters on FDA Approval of Next-Gen Medical Device
    InvestorPlace2 months ago

    Avinger Inc Stock Goes Gangbusters on FDA Approval of Next-Gen Medical Device

    The device that is sending Avinger Inc stock soaring with its FDA approval is the Pantheris Lumivascular atherectomy system. This system allows physicians to treat peripheral artery disease in a more accurate way than previous methods. The Pantheris Lumivascular atherectomy system makes better treatment possible by allowing for real-time intravascular imaging of arteries.

  • GlobeNewswire2 months ago

    Avinger Receives FDA Clearance of Next Generation Pantheris Device

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment of peripheral artery disease. Lumivascular is the only technology that combines real-time intravascular imaging with highly effective catheters for the treatment of PAD.

  • What Investors Should Know About Avinger Inc’s (NASDAQ:AVGR) Financial Strength
    Simply Wall St.2 months ago

    What Investors Should Know About Avinger Inc’s (NASDAQ:AVGR) Financial Strength

    While small-cap stocks, such as Avinger Inc (NASDAQ:AVGR) with its market cap of US$6.39M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of AVGR earnings conference call or presentation 14-May-18 8:30pm GMT

    Q1 2018 Avinger Inc Earnings Call

  • Associated Press2 months ago

    Avinger: 1Q Earnings Snapshot

    On a per-share basis, the Redwood City, California-based company said it had a loss of $5.37. The medical device maker posted revenue of $1.8 million in the period. In the final minutes of trading on Monday, ...

  • GlobeNewswire2 months ago

    Avinger Announces First Quarter 2018 Financial Results

    REDWOOD CITY, Calif., May 14, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, today reported results for the first quarter ended March 31, 2018.. First ...

  • ACCESSWIRE2 months ago

    Avinger, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Avinger, Inc. (NASDAQ: AVGR ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern Time. To listen ...

  • GlobeNewswire3 months ago

    Avinger to Announce First Quarter 2018 Financial Results on May 14, 2018

    REDWOOD CITY, Calif., May 04, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, today announced that it will release its financial results for the first ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Avinger and VIVUS

    NEW YORK, NY / ACCESSWIRE / May 2, 2018 / Positive developments sent shares of both Avinger and VIVUS higher on Tuesday. Avinger announced that its next generationPantheris Lumivascular atherectomy system with extended nosecone was featured in a live case transmission at Charing Cross International Symposium 2018. VIVUS announced that it has entered into a definitive agreement for the acquisition of PANCREAZE.

  • GlobeNewswire3 months ago

    Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Charing Cross International Symposium 2018

    REDWOOD CITY, Calif., April 30, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, announced that its next generation Pantheris ® Lumivascular atherectomy ...